Reduce HEAT: A Randomized Trial of Wearable Thermal Devices for ADT-Induced Hot Flashes

Inclusion Criteria:

* Patients with a clinical or pathologic confirmed diagnosis of prostate cancer
* Patients must be undergoing treatment with standard androgen deprivation therapy (i.e., GnRH agonist or antagonist) for ≥ 4 weeks. Patients must remain on ADT for the duration of the study (12 weeks); they may receive treatment with an androgen receptor pathway inhibitor (ARPI), radioligand therapy, or immunotherapy combined with ADT.
* Patients must report bothersome hot flash symptoms (defined as ≥ 28 hot flashes per week, perceived to be at least moderately bothersome to the patient), during a period of at least 30 days prior to entering the study.
* Age ≥18 years.
* ECOG performance status ≤ 2
* Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

* Pregnant and nursing women are excluded as prostate cancer is a disease of men.
* Participants with a concurrent diagnosis, including separate malignancy, that may limit life expectancy \< 6 months.
* Systemic antineoplastic therapy besides approved ARPI, radioligand therapy, and immunotherapy - enrollment in a clinical trial that is using SOC therapeutic options in these categories is allowed.